Project Grant 2410753

Award Date 8/1/24
Completion Date 7/31/27
Dollars Obligated $265K
Federal Grant Program
47.041
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90089, USA
Similar Awards
This $333,567 federal Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) will fund a collaborative research effort at Saint Louis University to determine the role of lipids in regulating lymphatic permeability. The project aims to develop an integrated computational and experimental approach to understand how lipids and the CD36 translocase regulate lymphatic vessel integrity and cell signaling. Researchers will use a systems biology methodology...
The National Science Foundation Division of Civil, Mechanical, and Manufacturing Innovation awarded a $299,990 Project Grant to Worcester Polytechnic Institute to investigate how tissue stiffness and fluid flow coordinate to regulate lymphatic capillary growth and function. This two-year award, issued on February 1, 2022 with a completion date of January 31, 2024, falls under the NSF Directorate for Engineering's CFDA #47.041 Engineering program. The program seeks to improve quality of life...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $808,121 to the University of Southern California (USC) to conduct research on the role of the mechanosensitive ion channel Piezo1 in lymphatic valve formation. The project aims to elucidate how lymphatic endothelial cells detect fluid flow forces and convert these signals into a biological program that orchestrates lymphatic...
This $429,114 federal Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) will fund the development and validation of a first-of-its-kind multi-tissue on-a-chip breast-skin platform. The platform will feature integrated blood and lymphatic vasculature to study the spatial and temporal processes of lymphovascular space invasion (LVSI), dermal lymphatic invasion (DLI), and skin metastasis in breast cancer. The central hypothesis is that the cross-talk...
The National Science Foundation (NSF) Engineering program (CFDA 47.041) has awarded a $200,000 Project Grant to Lutheran University Association Inc., doing business as Valparaiso University, to develop a liposomal drug delivery platform for the treatment of lymphatic filariasis - a neglected tropical disease. The project aims to optimize the lymphatic uptake of existing lymphatic filariasis drugs and improve their efficacy against adult filarial worms. This will be achieved by synthesizing and...
This National Science Foundation (NSF) Engineering Program (CFDA 47.041) award of $470,955 to Cornell University aims to develop a microfluidic cell culture platform to study breast cancer-associated secondary lymphedema. The 5-year project seeks to comprehend the regulation of lymphatic structure and function in breast cancer, and discover new treatment approaches for the over 150 million lymphedema patients worldwide. The research involves creating engineered lymphatic vessel models to analyze...
This $220,000 Project Grant award from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) aims to advance the understanding of how soft, deformable particles, such as oil droplets and cells, move through complex environments consisting of narrow constrictions and obstacles. The award to Emory University will systematically investigate the flow of bubbles and droplets through obstacle arrays, studying the effects of particle surface tension, obstacle density, size, and...
This National Science Foundation (NSF) Engineering Program project grant awarded to the Massachusetts Institute of Technology (MIT) provides $429,384 in funding to study how drug nanoparticles adhered to leukocyte (white blood cell) surfaces influence their mechanical properties and movement through microscale blood vessel networks. The 5-year research effort, from March 2024 to February 2029, will use a combination of biophysical models and microfluidic experiments to generate fundamental...
The National Science Foundation awarded a $550,781 Project Grant to the University of Southern California under the Engineering federal grant program (CFDA 47.041) to advance disease modeling for healthcare decision making from April 1, 2023 through March 31, 2028. The award will support developing a unified theoretical framework to incorporate individual-level disease simulations and compartmental models, with the goal of optimizing these approaches for single and repeated decision contexts...
This National Science Foundation (NSF) Engineering program (CFDA 47.041) Project Grant award of $342,318 supports research at the University of Wisconsin - Madison to develop a novel theoretical and computational framework for modeling the mechanical deformation and interactions of biomembranes with transport and electrochemical processes. The 3-year research project, starting on Sep 1, 2024, aims to create an open-source computational tool to model key biomembrane phenomena like endocytosis,...

This Project Grant award, with a total funding amount of $265,151.00, was provided by the National Science Foundation's (NSF) Engineering program (CFDA 47.041) to the University of Southern California. The project aims to use mathematical modeling and experiments to understand what regulates leakiness in the lymphatic system, with the goal of developing strategies to modulate lymphatic permeability. The research will investigate how lipids regulate CD36, a long-chain fatty acid translocase, and its impact on lymphatic vessel integrity and cell signaling. Key activities include developing mechanistic differential equation models, conducting biotinylated surface assays, immunofluorescence microscopy, direct measurements of lymphatic endothelial cell permeability, and morphological assessment of cell junctions. The validated models will be applied to predict strategies for modulating lymphatic permeability, which could have broader implications for addressing pathological changes in diseases like obesity and metabolic syndrome. No sub-awards are planned for this award, which has a performance period from Aug 1, 2024 to Jul 31, 2027.

Generated 5/13/25, 5:21 AM